Regeneron Pharmaceuticals Inc. ($REGN) Stock Forecast: Up 5.3% Today

What is Regeneron Pharmaceuticals Inc.?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a biotechnology company recognized for its innovative drug development. Today, the stock showed a significant upward trend.

Why is Regeneron Pharmaceuticals Inc. going up?

REGN stock is up 5.3% on Oct 1, 2025 13:56

• The momentum could be linked to the FDA's approval for the label extension of REGN's cholesterol drug Evkeeza, permitting its usage in children as young as one suffering from severe familial hypercholesterolemia.
• The FDA's endorsement for expanding the utilization of Regeneron's Evkeeza to infants with a rare cholesterol disorder may have instilled confidence in investors regarding the company's pipeline and prospective revenue.
• Anticipation surrounding Regeneron's forthcoming third-quarter financial and operating results announcement might also be fostering optimism among investors, who foresee strong performance and growth opportunities.

REGN Price Chart

REGN Technical Analysis

REGN News

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025

TARRYTOWN, N.Y., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open.

https://www.globenewswire.com/news-release/2025/09/30/3159045/0/en/Regeneron-to-Report-Third-Quarter-2025-Financial-and-Operating-Results-and-Host-Conference-Call-and-Webcast-on-October-28-2025.html

FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza

Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.

https://www.zacks.com/stock/news/2758634/fda-approves-label-extension-of-regns-cholesterol-drug-evkeeza

FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder - Regeneron Pharmaceuticals ( NASDAQ:REGN )

The U.S. Food and Drug Administration ( FDA ) on Friday approved Regeneron Pharmaceuticals, Inc.'s ( NASDAQ: REGN ) Evkeeza ( evinacumab-dgnb ) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of children from age 1 to less than 5 years old ...

https://www.benzinga.com/news/fda/25/09/47891829/fda-expands-use-of-regenerons-evkeeza-to-infants-with-rare-cholesterol-disorder

Trending Today

PancakeSwap ($CAKE) Crypto Forecast: Down 5.6% Today

XRP ($XRP) Crypto Forecast: Up 5.3% Today

Alcoa Corporation ($AA) Stock Forecast: Up 5.2% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 5.1% Today

Bausch + Lomb ($BLCO) Stock Forecast: Up 5.1% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Up 5.0% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 5.7% Today

Affirm Holdings Inc. ($AFRM) Stock Forecast: Up 5.1% Today

Western Digital Corporation ($WDC) Stock Forecast: Down 5.1% Today

ZCash ($ZEC) Crypto Forecast: Up 14.3% Today

Regeneron Pharmaceuticals Inc. Price History

30.04.2025 - REGN Stock was down 18.4%

• Mixed results from late-stage COPD studies conducted by Regeneron and SNY could have led to investor uncertainty and a sell-off of REGN shares.
• Meeting the primary endpoint in one trial but missing in another may have raised concerns about the drug's overall effectiveness and potential market approval.
• The uncertainty surrounding future plans for itepekimab in treating COPD could have contributed to the bearish market movement of REGN today.

18.08.2025 - REGN Stock was down 0.1%

• Despite promising results from a Phase 3 study on Garetosmab demonstrating a notable decrease in new bone lesions and favorable tolerability, the stock's decline may be linked to factors like general market sentiment or profit-taking.
• Concerns among investors may stem from the anticipation of a Wall Street trader's upcoming strategy unveiling, leading to apprehension and selling pressure on REGN shares.
• The drop in stock value may also reflect broader industry patterns or external market conditions affecting biotech stocks, resulting in a retreat in Regeneron's stock price.

01.07.2025 - REGN Stock was down 1.9%

• The stock had a bearish movement as analysts are expecting lower Q2 earnings compared to the year-ago period.
• The anticipated decrease in quarterly earnings to $8.43 per share, down from $11.56 per share, likely contributed to the bearish trend.
• Despite the long-term outperformance of Regeneron Pharmaceuticals, short-term concerns about earnings may have led to the negative market movement.
• Investors may be reacting to the revised forecasts ahead of the earnings call, causing a dip in the stock price.

05.01.2025 - REGN Stock was up 7.2%

• REGN experienced a strong bullish movement after reporting better-than-expected Q4 earnings, with adjusted EPS of $12.07 surpassing consensus estimates.
• The initiation of a dividend program and additional stock buyback program by Regeneron further boosted investor confidence in the company's financial stability and growth prospects.
• Despite a slight decline in Eylea sales in the United States due to competition, the overall sales growth of 10% to $3.79B and the surge in sales of other drugs like Libtayo contributed to the positive market response.
• The lawsuit against Regeneron for securities law violations may have initially caused some uncertainty, but the strong earnings report and strategic financial decisions overshadowed these concerns, leading to the bullish market movement.

08.04.2025 - REGN Stock was down 6.5%

• The stock price of Regeneron Pharmaceuticals experienced a significant decline today, despite a slight increase in the current market session.
• The downward trend in the stock price could be attributed to the overall market sentiment affecting biotech and pharmaceutical companies.
• Investors might be reacting to the stock's performance over the past month and year, where it has shown a notable decrease, possibly leading to profit-taking or market corrections.
• While Regeneron Pharmaceuticals has historically outperformed the market over the long term, short-term fluctuations can be influenced by various factors, including industry news and market conditions.

06.04.2025 - REGN Stock was down 5.1%

• REGN stock's decline could be linked to profit-taking following a period of market outperformance.
• Investor sentiment may be influenced by negative developments or uncertainties related to Regeneron Pharmaceuticals.
• Overall market trends or sector-specific factors might have contributed to REGN stock's downward trajectory.
• The decrease in Regeneron Pharmaceuticals' stock value could be a result of investors reallocating their investments to alternative opportunities.

12.02.2025 - REGN Stock was down 5.5%

• The bearish movement in REGN today could be attributed to profit-taking by investors after the stock's significant outperformance over the past 20 years.
• Positive discussions about the impressive historical returns of REGN might have influenced investors to sell their positions today, resulting in downward pressure on the stock.
• Market participants could be reevaluating their positions in REGN due to its high market capitalization, leading to a temporary decline in the stock price.

10.05.2025 - REGN Stock was up 5.1%

• The bullish movement in REGN stock today can be attributed to the positive news of expanding its pipeline through a strategic deal in the obesity drug market. Investors seem optimistic about the company's efforts to address challenges in its existing portfolio and capitalize on new opportunities for growth, leading to increased confidence and buying interest in the stock.

07.02.2025 - REGN Stock was up 5.1%

• REGN stock showed a strong bullish movement today.
• The positive recommendation for conditional marketing authorization for REGN's linvoseltamab to treat multiple myeloma is likely responsible for boosting investor confidence in the company's drug pipeline.
• This development hints at a possible new revenue source for Regeneron, leading to increased optimism among investors and influencing the bullish market movement.
• Investors may interpret this event as a significant milestone for Regeneron's expansion into the oncology market, contributing to the positive sentiment surrounding the stock.

29.03.2025 - REGN Stock was down 10.1%

• The bearish movement in REGN today could be attributed to investor concerns about the upcoming Q1 earnings.
• The focus on the performance of key drugs like Dupixent and Eylea HD may have led to uncertainty and profit-taking among investors.
• The market might be reacting to any potential signs of underperformance or lower-than-expected sales figures for these key products.
• Investors may be adjusting their positions in anticipation of the earnings, leading to the bearish movement in REGN today.

30.03.2025 - REGN Stock was up 5.5%

• Regeneron Pharmaceuticals Inc. (REGN) experienced a strong bullish movement today.
• The positive market sentiment could be attributed to potential breakthroughs in the company's research and development pipeline, driving investor confidence in its future prospects.
• Investors may also be reacting to favorable regulatory developments or promising clinical trial results, further boosting REGN's stock price.
• Overall, the bullish movement in REGN reflects growing optimism in the biotechnology sector and the company's ability to deliver innovative solutions to pressing healthcare challenges.

01.09.2025 - REGN Stock was up 5.3%

• The momentum could be linked to the FDA's approval for the label extension of REGN's cholesterol drug Evkeeza, permitting its usage in children as young as one suffering from severe familial hypercholesterolemia.
• The FDA's endorsement for expanding the utilization of Regeneron's Evkeeza to infants with a rare cholesterol disorder may have instilled confidence in investors regarding the company's pipeline and prospective revenue.
• Anticipation surrounding Regeneron's forthcoming third-quarter financial and operating results announcement might also be fostering optimism among investors, who foresee strong performance and growth opportunities.